Stomach cancer (credit: canva)
Stomach cancer is a type of cancer that develops in the lining of the stomach. Also, known as Gastric cancer, it affects the elderly more than the adult. According to the American Cancer Society, about 6 of every 10 people diagnosed with stomach cancer each year are 65 or older. Also, the lifetime risk of developing stomach cancer is higher in men (about 1 in 101) than in women (about 1 in 155).
A health expert, speaking to a leading media house, emphasized five common symptoms of stomach cancer that should not be ignored:
1. Unexplained weight loss: Losing weight without trying or experiencing an unexplained drop in appetite, which may signal cancer progression.
2. Pain in the upper part of the abdomen: Persistent or occasional pain in the stomach area, often after eating, can become more severe as the condition progresses.
3. Frequent vomiting after meals: Nausea, sometimes accompanied by vomiting, may occur especially after meals and is linked to cancer blocking or irritating the stomach.
4. Vomiting blood, which may appear coffee-colored: This can indicate bleeding in the stomach, often caused by ulcers or tumors, and requires immediate medical attention.
5. Black, tarry stools: This occurs when blood from the stomach is digested and passed through the intestines, signaling potential internal bleeding
There are also other concerning signs that should not be overlooked such as jaundice, unexplained weight loss, early onset of diabetes, dark stools, and loss of appetite. Health experts strongly advise seeking immediate medical attention if you notice any of these symptoms. If you or a loved one experience these signs, it's crucial to visit a physician for a thorough evaluation to rule out serious underlying health conditions.
Oncologist Dr Pankaj Kumar Pande, Director–Surgical Oncology, Max Super Specialty Hospital, Shalimar Bagh, Delhi explained that this form of cancer spreads through three main pathways: Direct spread, lymphatic spread, and bloodstream.
1. Direct Spread: In its early stages, stomach cancer can invade nearby tissues and grow into the deeper layers of the stomach or spread to surrounding organs such as the oesophagus, liver, pancreas, or intestines.
2. Lymphatic Spread: Cancer cells can travel through the lymphatic system. The most common areas affected are the regional lymph nodes near the stomach, particularly those around the liver and diaphragm.
3. Bloodstream: "Cancer cells can enter the bloodstream and travel to distant parts of the body," which is a common route for stomach cancer to metastasize to distant organs.
He further explained that cancerous cells spread from the original tumour to other parts of the body through a process called Metastasis. The most common sites for the spread are the liver, lymph nodes, peritoneum, lungs, bones, and ovaries.
Credit: AI image
There are currently no proven treatments to reverse Alzheimer’s but researchers are actively looking into treatments and therapies that could decrease the pace of disease progression and cognitive decline.
An experimental drug may be on the path to achieve that goal after it was able to slow cognitive decline by 38% over two years in people with early-stage Alzheimer’s. The development came to light after new clinical trial findings were announced by pharmaceutical company Biogen.
The experimental drug that targets a protein linked to Alzheimer's disease is called diranersen (BIIB080). It is equipped to reduce levels of tau, a protein that accumulates abnormally in the brains of people with Alzheimer's disease and causes damage to nerve cells.
Results from the Phase 2 CELIA trial, presented at the Clinical Trials on Alzheimer's Disease (CTAD) 2026 conference, showed that patients receiving the lowest dose of diranersen experienced more cognitive decline at two years than was reported at the 18-month assessment.
The 60 mg dose, administered through an injection into the fluid surrounding the spinal cord twice a year, slowed cognitive decline by 38% on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) scale at 96 weeks. This was an improvement from the 26% slowing that was observed at 76 weeks.
The two-year results corresponded to a 1.09-point difference on the CDR-SB scale compared to the control group. The scale measures changes in memory, thinking abilities and the ability to do everyday activities.
Tau is a protein that normally helps maintain the structure and stability of nerve cells. But, in Alzheimer's disease, tau can become abnormal, clump together and form structures known as neurofibrillary tangles inside brain cells.
They interfere with the normal functioning of nerve cells and can lead to progressive brain damage, memory loss and cognitive decline, symptoms usually seen in Alzheimer’s patients.
Diranersen belongs to a class of medicines that work by targeting genetic messages involved in producing proteins. In this case, diranersen targets the messenger RNA (mRNA) produced by the MAPT gene, which carries instructions for making tau protein. By targeting this genetic message, the drug aims to reduce the production of tau at source.
Recently approved Alzheimer's treatments like lecanemab and donanemab target amyloid-beta plaques, another abnormal protein accumulation associated with the disease. They work by helping the body clear amyloid deposits from the brain and have demonstrated modest slowing of cognitive decline in people with early Alzheimer's.
Diranersen works differently by targeting tau production rather than amyloid accumulation.
Also read: Older Adults Receiving High-Dose Flu Shots Show Lower Alzheimer's Risk: Study
Biogen reported that diranersen was well tolerated over the two-year observation period as no new safety concerns came up.
Side effects mostly included headaches and back pain, which could have been due to lumbar puncture procedure used to administer the drug. A small number of participants also experienced confusion.
Unlike some existing Alzheimer's treatments, the trial did not report cases of amyloid-related brain swelling.
Diranersen is still undergoing clinical development and is not approved by the US Food and Drug Administration (FDA) or other regulatory authorities.
Credit: AI
India is set to launch its first indigenously developed vaccine against H5N1 bird flu virus in chickens on November 20, as new outbreaks have been emerging in different parts of the country.
Developed by scientists at ICAR-National Institute of High Security Animal Diseases (ICAR-NIHSAD), the inactivated vaccine targets H5N1 Clade 2.3.2.1a, a strain that caused several bird flu outbreaks among chickens in India.
According to the Ministry of Agriculture and Farmers' Welfare, this marks a significant development in poultry and public health as there is no commercial vaccine against this particular H5N1 strain.
Bird flu, medically known as avian influenza, is a viral infection that primarily affects birds. Highly pathogenic avian influenza (HPAI) strains, including H5N1, can cause severe illness and extremely high mortality among infected poultry.
Since the first detection of bird flu in India in 2006, the country has reported more than 500 combined outbreaks involving H5N1 and H5N8 subtypes.
These outbreaks can have serious economic consequences. Infected birds may need to be culled to prevent further transmission. The 2006 outbreak alone resulted in estimated direct and indirect losses of Rs 2,200–3,000 crore.
The newly developed vaccine can help strengthen the country’s ability to prevent outbreaks and protect poultry populations against the H5N1 strain currently circulating in the country.
Also read: UK Reports Its First Human Case Of Bird Flu
The indigenous vaccine contains an inactive version of the virus that cannot replicate and infect. When administered, it exposes the chicken's immune system to viral components, just enough to allow it to recognise the virus and develop an immune response.
If the vaccinated bird encounters the actual virus later, its immune system can recognise it and respond more effectively.
The vaccine announcement comes just as fresh reports of bird flu infections in poultry have emerged.
In Tamil Nadu's Cuddalore district, H5N1 infections were confirmed following sudden deaths among chickens at poultry farms. More than 35,000 birds had died by November 13, prompting authorities to initiate containment and culling efforts.
Andhra Pradesh has also reported H5N1 infections in poultry, prompting restrictions and surveillance measures.
The indigenous vaccine is an important step in India's poultry disease-control efforts, but its introduction does not mean bird flu outbreaks will be prevented completely.
Its effectiveness depends on vaccination coverage, administration, monitoring of viral strains and compliance with farm biosecurity measures.
Also read: New Strain Of Bird Flu Detected In US, Here’s How You Can To Stay Protected
Although H5N1 primarily affects birds, the virus can occasionally cross the zoonotic barrier and infect humans, especially those who have long-term contact with infected birds, their secretions or contaminated environments.
Human infections can cause symptoms ranging from mild respiratory illness to severe pneumonia and, in some cases, death.
According to the World Health Organization (WHO), 1,003 human cases of H5N1 infection, including 479 deaths, had been reported across 25 countries since 2003, as cited in the Indian government's November 18 announcement.
Human infections, however, remain relatively uncommon and sustained human-to-human transmission has not been established.
People working with poultry should avoid handling sick or dead birds without protective equipment. Unusual bird deaths should be reported to veterinary authorities.
Credit: iStock
Lung cancer remains the leading cause of cancer deaths in the US, with 229,410 new cases expected this year, according to a annual report from the American Lung Association's (ALA).
The Association's ninth annual State of Lung Cancer report stated that although five-year survival has improved, low screening rates, delayed diagnosis and unequal access to treatment remain major challenges.
Harold Wimmer, President and CEO of the ALA, said, “the national five-year survival rate has increased significantly, from 18.1% to 31.0%, and screening rates have also continued to rise.”
However, he warned that progress has not reached all communities equally.
“Awareness is still low and challenges remain. We must continue to drive progress on lung cancer screening, comprehensive biomarker testing, clinical trials and effective treatments to help people live longer, fuller lives after a lung cancer diagnosis.”
Only 29.3% of lung cancer cases are diagnosed early. Rhode Island recorded the highest early diagnosis rate at 38%, while Hawaii had the lowest at 21.9%.
More concerning, 20.9% of patients received no treatment. The ALA identified potential barriers including lack of awareness, stigma, fatalism after diagnosis and treatment costs.
No-treatment rates ranged from 13.4% in Rhode Island to 36.7% in Nevada.
Annual low-dose CT scans can detect lung cancer early in people at high risk. Yet only 24.4% of eligible Americans underwent screening.
Massachusetts recorded the highest screening rate at 38.7%, while South Dakota had the lowest at 13.5%.
Other Key Findings
Smoking is a major risk factor. Others include radon gas, air pollution and secondhand smoke. The ALA recommends radon testing, reducing air pollution and stronger tobacco-control measures, including smoke-free laws and access to smoking cessation services.
Cleveland Clinic defines lung cancer as a malignant disease that happens when cells in the lung tissue grow out of control and form tumors. It is the leading cause of cancer deaths worldwide.
Lung cancer may cause no noticeable symptoms in its early stages. Symptoms can include persistent cough, coughing up blood, chest pain, unexplained weight loss, shortness of breath, recurrent chest infections and fatigue.
These symptoms should not be ignored. Early detection improves the chances of successful treatment, particularly before the cancer spreads.
© $2026 Times Horizon Private Limited